1. Home
  2. CASH vs IMCR Comparison

CASH vs IMCR Comparison

Compare CASH & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASH
  • IMCR
  • Stock Information
  • Founded
  • CASH 1954
  • IMCR 2008
  • Country
  • CASH United States
  • IMCR United Kingdom
  • Employees
  • CASH N/A
  • IMCR N/A
  • Industry
  • CASH Major Banks
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CASH Finance
  • IMCR Health Care
  • Exchange
  • CASH Nasdaq
  • IMCR Nasdaq
  • Market Cap
  • CASH 1.8B
  • IMCR 1.8B
  • IPO Year
  • CASH N/A
  • IMCR 2021
  • Fundamental
  • Price
  • CASH $80.20
  • IMCR $35.17
  • Analyst Decision
  • CASH Buy
  • IMCR Buy
  • Analyst Count
  • CASH 2
  • IMCR 10
  • Target Price
  • CASH $91.00
  • IMCR $58.13
  • AVG Volume (30 Days)
  • CASH 203.0K
  • IMCR 260.6K
  • Earning Date
  • CASH 07-28-2025
  • IMCR 08-07-2025
  • Dividend Yield
  • CASH 0.25%
  • IMCR N/A
  • EPS Growth
  • CASH 10.71
  • IMCR N/A
  • EPS
  • CASH 7.36
  • IMCR N/A
  • Revenue
  • CASH $731,383,000.00
  • IMCR $333,581,000.00
  • Revenue This Year
  • CASH $14.15
  • IMCR $26.82
  • Revenue Next Year
  • CASH $5.99
  • IMCR $8.15
  • P/E Ratio
  • CASH $10.90
  • IMCR N/A
  • Revenue Growth
  • CASH 6.51
  • IMCR 25.75
  • 52 Week Low
  • CASH $60.42
  • IMCR $23.15
  • 52 Week High
  • CASH $86.00
  • IMCR $40.88
  • Technical
  • Relative Strength Index (RSI)
  • CASH 48.87
  • IMCR 53.52
  • Support Level
  • CASH $79.77
  • IMCR $32.20
  • Resistance Level
  • CASH $84.75
  • IMCR $37.63
  • Average True Range (ATR)
  • CASH 2.00
  • IMCR 1.21
  • MACD
  • CASH -0.42
  • IMCR 0.03
  • Stochastic Oscillator
  • CASH 8.50
  • IMCR 53.90

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: